Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating [Yahoo! Finance]
Evolus (NASDAQ:EOLS) was given a new $15.00 price target on by analysts at Mizuho.
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance]
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance Canada]
Evolus (NASDAQ:EOLS) had its price target lowered by analysts at HC Wainwright from $20.00 to $13.00. They now have a "buy" rating on the stock.